Private equity is buying up more methadone clinics. Access to the lifesaving drug isn’t getting easier.
Three times a week, Amber Titus wakes up at 5 a.m. to get ready for the 45-minute drive to the methadone clinic.
Titus, 38, and her husband live with their two young children in Bisbee Junction, Arizona, a rural community near the U.S.-Mexico border. The couple started taking methadone, a medication that treats opioid addiction, in early 2025.
“It’s been a godsend,” she said.
But accessing methadone is not easy. The closest place they can receive treatment is a clinic in Sierra Vista, about 30 miles from their home.
The clinic opens on weekdays at 4:30 a.m. but closes before midday. Titus has to get her methadone dose and arrive at work in Bisbee before her shift starts at 9 a.m.
Arriving just 10 to 15 minutes late for an appointment can mean missing a dose because rules are so strict, she said, even when the clinic is still open.
That’s the routine when they have their own transportation. In August, their car was totaled in a crash. Until they got another one, Titus called Medicaid, her insurance provider, to schedule rides to the clinic.
“They said they’d be at my house at 6 o'clock in the morning,” Titus told The Conversation. The driver was late every day. “I missed my methadone dose for the whole week,” she said.
Nationwide, more than 120 people a day died from opioid overdoses in 2025, according to federal estimates. Methadone is one of the most effective medications for opioid use disorder, cutting the risk of fatal overdose by roughly half. Yet only 22% of people with the disorder ever receive it.
For more than five decades, only specialized, government-approved clinics, known as opioid treatment programs, have dispensed methadone, not regular doctors or pharmacies. Many clinics require patients to show up in person every single day, with average one-way drive times approaching 50 minutes in rural communities.
Today, private equity firms have acquired large shares of the market for methadone clinics, telling lawmakers their capital has expanded treatment and modernized care.
I am a healthcare economist at Brown University who studies how private equity is reshaping American medicine. My recent research on private equity’s growing footprint in addiction treatment, co-authored with researchers from the University of Pittsburgh and RAND, found that despite acquiring over one-third of methadone clinics in the U.S., private equity investments have not expanded methadone availability or the construction of new facilities.
This research has informed federal investigations into the role of private equity in expanding access to medications for addiction treatment. Currently, U.S. Sen. Maggie Hassan, D-N.H., has an investigation into three of the country’s largest methadone clinic operators, citing concerns that they oppose expanding treatment access for financial reasons rather than patient safety.
Why methadone fits the private equity model
Because methadone is so tightly regulated, opioid treatment programs are, in effect, a government-created monopoly.
In most of the country, if you want methadone, there’s a short list of clinics licensed to give it to you and no other way to get it. Moreover, people with opioid use disorder generally must travel to opioid treatment programs every day, where staff must observe them taking methadone, with strict limits on how much methadone patients can take home and when they can do so.
Take-home methadone varies based on the state, time in treatment and clinician discretion. Only 19% of people who received take-home methadone received three or more days’ supply.
That kind of guaranteed, captive demand is exactly the sort of investment that can be profitable for private equity investors.........
